Literature Cited

  • 1
    Russmann S,Kullak-Ublick GA,Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009; 16: 30413053.
  • 2
    Shaw PJ,Ganey PE,Roth RA. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 2010; 118: 718.
  • 3
    Deng X,Luyendyk JP,Ganey PE,Roth RA. Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev 2009; 61: 262282.
  • 4
    Cosgrove BD,King BM,Hasan MA,Alexopoulos LG,Farazi PA,Hendriks BS,Griffith LG,Sorger PK,Tidor B,Xu JJ, et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 2009; 237: 317330.
  • 5
    Waring JF,Liguori MJ,Luyendyk JP,Maddox JF,Ganey PE,Stachlewitz RF,North C,Blomme EA,Roth RA. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther 2006; 316: 10801087.
  • 6
    Teng S,Piquette-Miller M. Regulation of transporters by nuclear hormone receptors: implications during inflammation. Mol Pharm 2008; 5: 6776.
  • 7
    Glavinas H,Krajcsi P,Cserepes J,Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004; 1: 2742.
  • 8
    Yamaguchi S,Zhao YL,Nadai M,Yoshizumi H,Cen X,Torita S,Takagi K,Hasegawa T. Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother 2006; 50: 8087.
  • 9
    Morgan ET,Goralski KB,Piquette-Miller M,Renton KW,Robertson GR,Chaluvadi MR,Charles KA,Clarke SJ,Kacevska M,Liddle C, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008; 36: 205216.
  • 10
    Kostrubsky SE,Strom SC,Kalgutkar AS,Kulkarni S,Atherton J,Mireles R,Feng B,Kubik R,Hanson J,Urda E, et al. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 2006; 90: 451459.
  • 11
    Fernandez C,Buyse M,German-Fattal M,Gimenez F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J Pharm Pharm Sci 2004; 7: 359371.
  • 12
    Fardel O,Le Vee M. Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. Expert Opin Drug Metab Toxicol 2009; 5: 14691481.
  • 13
    Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16: 56515661.
  • 14
    Jigorel E,Le Vee M,Boursier-Neyret C,Parmentier Y,Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 2006; 34: 17561763.